In a notable surge, AngioDynamics Inc. (NASDAQ:ANGO) stock has reached a 52-week high, touching $9.59 USD. According to InvestingPro data, the company maintains a strong financial position with more cash than debt and a healthy current ratio of 2.25x. This peak reflects a significant uptrend for the medical device company, which has seen an impressive 45.77% increase in its stock value over the past year. Investors and analysts are closely monitoring AngioDynamics as it outperforms expectations, attributing the rise to strategic business moves and a robust product pipeline that could signal continued growth in the healthcare sector. The company's strong performance over the year has positioned it as a standout in its industry, with market sentiment remaining bullish on its prospects. Based on InvestingPro analysis, the stock appears slightly undervalued, with analysts setting price targets between $12 and $14. Discover more insights and 8 additional ProTips in the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, AngioDynamics has made significant strides in both its product offerings and financial performance. The medical technology company recently received CPT Category I codes for its NanoKnife System, allowing broader patient access to minimally invasive treatments for prostate and liver lesions. This development, effective January 1, 2026, is expected to enable healthcare providers to obtain reimbursement for performing Irreversible Electroporation (IRE) ablation procedures using the NanoKnife System.
Simultaneously, AngioDynamics reported a slight 1.1% year-over-year increase in net sales for the first quarter of fiscal year 2025, totaling $67.5 million. Despite a minor sales miss, analysts from H.C. Wainwright and Oppenheimer maintained a positive outlook on the company, affirming a Buy and Outperform rating respectively. The Med Tech segment of AngioDynamics, including Auryon and AlphaVac products, saw a revenue increase of nearly 9%, offsetting a 4% decline in the Med Device segment.
Moreover, the company has reiterated its full-year 2025 guidance, expecting net sales between $282-288 million. In other recent developments, AngioDynamics has announced a transition to outsourced manufacturing, projected to result in significant annual savings by fiscal 2027. These recent developments reflect changes in the company's operational strategy and market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.